BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06), Zacks reports.

BioCryst Pharmaceuticals Trading Down 1.9 %

Shares of BCRX opened at $9.21 on Monday. The firm’s 50-day moving average price is $8.01 and its 200-day moving average price is $7.84. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -15.10 and a beta of 1.75. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $9.50.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on BCRX shares. Barclays lifted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Needham & Company LLC lifted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Evercore ISI lifted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. JMP Securities restated a “market outperform” rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.50.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.